Opdivo (Nivolumab) vs Loqtorzi (toripalimab-tpzi)

Opdivo (nivolumab) and Loktorsi (toripalimab-tpzi) are both immune checkpoint inhibitors, but they target different proteins; nivolumab blocks the PD-1 protein, while toripalimab targets both PD-1 and PD-L1, potentially offering a broader immune response. Opdivo has been extensively studied and is approved for various cancers, including melanoma, lung cancer, and kidney cancer, with a well-established safety and efficacy profile. Loktorsi, on the other hand, is one of the newer PD-1 inhibitors and may have different indications and side effect profiles, so a healthcare provider would consider the specific type of cancer, patient's medical history, and current health to determine the most appropriate treatment option.

Difference between Opdivo and Loqtorzi

Metric	Opdivo (Nivolumab)	Loqtorzi (toripalimab-tpzi)
Generic name	Nivolumab	Toripalimab
Indications	Various types of cancers including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and others.	Approved in China for melanoma, nasopharyngeal carcinoma, and urothelial carcinoma. Not yet approved in the United States.
Mechanism of action	PD-1 inhibitor that enhances the immune response against cancer cells.	PD-1 inhibitor that enhances the immune response against cancer cells.
Brand names	Opdivo	Loqtorzi (in China), TUOYI (in China)
Administrative route	Intravenous infusion	Intravenous infusion
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, and others.	Fatigue, fever, decreased appetite, thyroid dysfunction, and others.
Contraindications	Known hypersensitivity to nivolumab or any of its excipients.	Known hypersensitivity to toripalimab or any of its excipients.
Drug class	Programmed death receptor-1 (PD-1) blocking antibody	Programmed death receptor-1 (PD-1) blocking antibody
Manufacturer	Bristol Myers Squibb	Shanghai Junshi Biosciences Co., Ltd.

Efficacy

Efficacy of Opdivo (Nivolumab) in Head and Neck Cancer

Opdivo (Nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody used in the treatment of several types of cancer, including head and neck squamous cell carcinoma (HNSCC). In patients with recurrent or metastatic HNSCC, Opdivo has demonstrated a significant improvement in overall survival compared to other standard therapies. Clinical trials have shown that Opdivo can extend survival for patients with HNSCC who have progressed on or after platinum-based therapy. The efficacy of Opdivo in this patient population is attributed to its mechanism of action, which involves the reactivation of the immune system to recognize and attack cancer cells.

One pivotal study that highlights the efficacy of Opdivo in head and neck cancer is the CheckMate-141 trial. This Phase III clinical trial found that Opdivo improved median overall survival to 7.5 months compared to 5.1 months in the control group treated with standard therapies. Additionally, the one-year survival rate was significantly higher in the Opdivo-treated group. These results have led to the approval of Opdivo for the treatment of patients with HNSCC who have disease progression during or after platinum-based chemotherapy.

Efficacy of Loqtorzi (toripalimab-tpzi) in Head and Neck Cancer

Loqtorzi (toripalimab-tpzi) is a relatively new addition to the class of immune checkpoint inhibitors and is used for the treatment of various cancers, including head and neck cancer. While comprehensive data on the efficacy of Loqtorzi in head and neck cancer is still emerging, preliminary studies have shown promise. Toripalimab has been evaluated in clinical trials for its potential to improve outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma, a type of head and neck cancer.

In these clinical studies, toripalimab has been used both as a monotherapy and in combination with chemotherapy. Early results suggest that toripalimab can produce a meaningful antitumor response in a subset of patients with head and neck cancer. The efficacy of toripalimab is measured by objective response rates, progression-free survival, and overall survival, with some studies reporting favorable outcomes in these endpoints. As more data becomes available, the role of Loqtorzi in the treatment of head and neck cancer will be better defined, potentially expanding the therapeutic options for patients with this challenging disease.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Loqtorzi

Food and Drug Administration (FDA), USA

Access Opdivo or Loqtorzi today

If Opdivo or Loqtorzi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Loqtorzi

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: